LGND

LIGAND PHARMACEUTICALS INC

LGND·53220K504·US·Common Stock·Healthcare - Biotechnology-13D/G

LGND (LIGAND PHARMACEUTICALS INC) is held by 174 institutional investors as of Q2 2026. Largest holders: BlackRock, Inc. ($980.2M), Invesco Ltd. ($379.8M), VANGUARD PORTFOLIO MANAGEMENT LLC ($359.8M). Net institutional sentiment: Mixed. In Q2 2026, 1 member of Congress and 108 funds bought LGND.

174
Holders
(15 Elite)
$5.5B
Total Value
60% (180)
Consensus
108 buying - 72 selling
13F: Insider & Congress: Updated regularly
LGND

Smart Money Verdict

View all
Loading verdict
Held by 174 funds
15 elite

Who's Trading

Source dates: Price Aug 31, 2026 · Insiders Aug 14, 2026 · Activists Aug 13, 2026 · Congress Jun 8, 2026

ActivistInvesco Ltd.Invesco Ltd.6.1%Aug 13, 2026
InsiderEOEspinoza OctavioExercise 2K shAug 12, 2026
InsiderEOEspinoza OctavioExercise 3K shAug 12, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
3.1M(+4.7%)$980.2M0.0%+138.92%
33
Increased
1.2M(+45.9%)$379.8M0.0%+33.66%
42
Increased
1.1M(+3.5%)$359.8M0.0%+34.86%
32
Increased
870,950(+2.7%)$275.3M0.0%+35.39%
32
Increased
826,539(+6.1%)$261.3M0.0%+199.26%
33
Increased
762,827(+28.0%)$241.1M0.0%+36.49%
38
Increased
752,044(+31.2%)$237.7M0.1%+41.60%
39
Increased
659,911(+30.8%)$208.6M1.3%+91.43%
61
Increased
589,020(+5.4%)$186.2M0.0%+153.49%
32
Decreased
568,371(-0.9%)$179.7M0.3%+47.47%
0
Increased
429,314(+1.0%)$135.7M0.0%+273.41%
30
Decreased
375,762(-8.7%)$118.8M0.0%+112.73%
0
Decreased
323,245(-15.2%)$102.2M0.0%+69.42%
0
Decreased
291,805(-17.4%)$92.2M0.1%+210.34%
0
Increased
257,389(+1.3%)$81.4M0.0%+216.15%
30
Decreased
253,764(-16.3%)$80.2M0.0%+65.14%
0
Decreased
249,611(-18.5%)$78.9M0.0%+264.99%
0
Increased
248,355(+169x)$78.5M0.1%-11.03%
48
Decreased
210,427(-1.2%)$66.5M0.0%+154.32%
0
Increased
200,699(+20.0%)$63.4M0.0%+117.07%
35

Showing 1-20 of 194

1 / 10
LGNDLGNDLIGAND PHARMACEUTICALS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used